Clovis Oncology Inc.

(CLVS) Trade

By |

Profile

Clovis Oncology Inc is operative in the healthcare sector based in the United States. As a pharmaceutical manufacturer, it is focused on developing and commercializing anti-cancer agents. Its suite of product candidates includes Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor for the treatment of non-small cell lung cancer. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. The company's revenue primarily depends on the sale of Rucaparib in the United States market.

Contact Information

Website: www.clovisoncology.com
Email: bburkart@clovisoncology.com
Main Phone: +1 303 625-5000
Address: 5500 Flatiron Parkway
Address 2: Suite 100
State: CO
City / Town: Boulder
Country: USA
Postal Code: 80301

Issuer Information

Exchange: NGS
CEO: Patrick J. Mahaffy
Employees: 360
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 20.12 $ -1.51 (-6.98%)
Last Price 20.12 Change $ -1.51 Change % -6.98 Tick N/A
Bid 20.10 Bid Size 400.00 Ask 20.11 Ask Size 500.00
Open 21.00 High 21.57 Low 18.60 Prev Close 21.63
Last Trade Volume 3.3 mi 52 Wk Hi 69.02 52 Wk Low 11.50
Market Cap 1.1 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 52,711,827.00 EPS (TTM) -6.16 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 15 61
Number of Buys 7 24
Number of Sells 8 37
Net Activity -27459 -429324
Last 10 Buys Shares
Edward J. McKinley 1,000
Edward J. McKinley 1,000
Edward J. McKinley 1,000
Edward J. McKinley 1,000
Erle T. Mast 1,000
Thorlef Spickschen 1,000
Gillian C. Ivers-Read 1,000
Edward J. McKinley 1,000
Paul H. Klingenstein 1,000
James C. Blair 1,000
Last 10 Sell Shares
Thorlef Spickschen 1,000
Thorlef Spickschen 1,000
Thorlef Spickschen 1,000
Gillian C. Ivers-Read 1,000
Gillian C. Ivers-Read 1,000
Thorlef Spickschen 1,000
Gillian C. Ivers-Read 1,000
Thorlef Spickschen 1,000
Gillian C. Ivers-Read 1,000
Gillian C. Ivers-Read 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 97 97 97 97
Low Target Price Estimate 72 72 72 72
Mean Target Price Estimate 84.14 84.14 84.14 84.14
Standard Deviation 9.08 9.08 9.08 9.08
Date of Most Recent Estimate 06/05/18 05/09/18 05/09/18 06/05/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 6 7 7 8
Moderate Buy 1 1 2 2
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.56 1.5 1.5 1.46